Table 1 Clinical characteristics of BS patients and healthy controls
BS patients (n = 23) | Healthy controls (n = 28) | ||
|---|---|---|---|
Female, n (%) | 12 (52%) | 21 (75%) | ns |
Age, median (range) | 54 (30–74) | 56 (28–80) | ns |
HLA-B51 positive, n (%) | 11 (47%) | ||
Disease duration, years, median (range) | 15 (1–37) | ||
Active symptoms at the time of participation in the study, n (%) | 13 (56%) | ||
Oral aphthous ulcerations | 3 (13%) | ||
Genital ulcers | 0 (0%) | ||
Uveitis | 0 (0%) | ||
Cutaneous lesions | 7 (30%) | ||
Pathergy | 2 (8%) | ||
Arthralgia/arthritis | 5 (21%) | ||
Intestinal lesions | 0 (0%) | ||
Vascular lesions | 1 (4%) | ||
Neurologic disease | 0 (0%) | ||
Treatment at the time of participation in the study, n (%, dosage) | |||
Colchicine | 16 (69%, 0.25–1.5 mg/day) | ||
Prednisolone | 9 (39%, 1.5–7.0 mg/day) | ||
Cyclosporine | 5 (21%, 25–175 mg/day) | ||
Other immunomodulatory or immunosuppressive drugs (azathioprine, salazosulfapyridine, mesalazine, methotrexate) | 7 (30%) | ||
No treatment | 2 (8%) | ||